



**HAL**  
open science

## New insights in COVID-19-associated chilblains: A comparative study with chilblain lupus erythematosus

Gilles Battesti, Jihane El Khalifa, Nour Abdelhedi, Valentine Ferre, Fabrice Bouscarat, Catherine Picard-Dahan, Florence Brunet-Possenti, Gilles Collin, Justine Lavaud, Patrick Le Bozec, et al.

### ► To cite this version:

Gilles Battesti, Jihane El Khalifa, Nour Abdelhedi, Valentine Ferre, Fabrice Bouscarat, et al.. New insights in COVID-19-associated chilblains: A comparative study with chilblain lupus erythematosus. *Journal of The American Academy of Dermatology*, Elsevier, 2020, 83 (4), pp.1219-1222. 10.1016/j.jaad.2020.06.1018 . hal-03295375

**HAL Id: hal-03295375**

<https://hal-cnrs.archives-ouvertes.fr/hal-03295375>

Submitted on 9 Sep 2022

**HAL** is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.



Distributed under a Creative Commons Attribution-NonCommercial 4.0 International License

1 **New insights in COVID-19-associated chilblains: a comparative study with chilblain lupus**  
2 **erythematosus**

3 Gilles Battesti, MD<sup>1</sup>; Jihane El Khalifa, MD<sup>2</sup>; Nour Abdelhedi, MD<sup>2</sup>; Valentine Ferre, PharmD<sup>3</sup>; Fabrice  
4 Bouscarat, MD<sup>2</sup>; Catherine Picard-Dahan, MD<sup>2</sup>; Florence Brunet-Possenti, MD<sup>2</sup>; Gilles Collin<sup>3</sup>, Justine  
5 Lavaud, MD<sup>2</sup>; Patrick Le Bozec, MD<sup>2</sup>; Marion Rousselot, MD<sup>2</sup>; Amélie Tournier, MD<sup>2</sup>; Coralie Lheure,  
6 MD<sup>2</sup>; Anne Couvelard, MD, PhD<sup>1</sup>; Salima Hacein-Bey-Abina, PharmD, PhD<sup>4,5</sup>; Amine.M Abina, MD,  
7 PhD<sup>4,6</sup>; Charlotte Charpentier, PharmD, PhD<sup>3</sup>; Sabine Mignot, PharmD, PhD<sup>7</sup>; Pascale Nicaise,  
8 PharmD, PhD<sup>7</sup>; Diane Descamps, MD, PhD<sup>3</sup>; Lydia Deschamps, MD<sup>1</sup>; Vincent Descamps, MD, PhD<sup>2</sup>

- 9  
10 1. Department of Pathology, Bichat Hospital, 46 rue Henri Huchard 75877 Paris, France.  
11 2. Department of Dermatology, Bichat Hospital, 46 rue Henri Huchard 75877 Paris, France.  
12 3. Department of Virology, Bichat Hospital, 46 rue Henri Huchard 75877 Paris, France.  
13 4. UTCBS CNRS UMR 8258, INSERM U1267, Faculté de Pharmacie de Paris, Université de Paris, 4 av.  
14 de l'observatoire, 75006 Paris, France  
15 5. Clinical Immunology Laboratory, Groupe Hospitalier Universitaire Paris-Sud, Hôpital Kremlin-  
16 Bicêtre, Assistance Publique-Hôpitaux de Paris, 78, r. du Général-Leclerc, 94270 Le-Kremlin-Bicêtre,  
17 France.  
18 6. Cerba Healthcare, Cerballiance-Ile-de-France Ouest, Hôpital Privé de l'Ouest Parisien, 14 Rue  
19 Castiglione del Lago, 78190 Trappes  
20 7. Department of Immunology, Bichat Hospital, 46 rue Henri Huchard 75877 Paris, France.

21  
22 Corresponding author and reprint requests:  
23 Vincent Descamps, MD, PhD, Department of Dermatology, Bichat Hospital, 46 rue Henri Huchard  
24 75877 Paris, France.  
25 Telephone: 01 40 25 73 00  
26 Fax: 01 40 25 73 03  
27 E-mail: [vincent.descamps@aphp.fr](mailto:vincent.descamps@aphp.fr)

28  
29 Funding sources: None  
30 Conflicts of Interest: None  
31 IRB approval status: Approved by the institutional review board of HUPNVS, Paris 7 University, AP-HP  
32 (IRB 00006477)  
33 Statement of any prior presentation: none

34  
35 Manuscript word count: 499 words  
36 References: 5  
37 Figures: 0  
38 Supplementary figures: 0  
39 Tables: 2  
40 Supplementary tables: 0

41  
42  
43  
44  
45

46 **Abbreviation and acronym list:**

47 Epidemic chilblain: EC

48 Chilblain lupus erythematosus: CLE

49 Type-1 interferon: IFN-1

50 Plasmacytoid dendritic cells: pDCs

51 Antineutrophils cytoplasmic antibodies: ANCA

52

53

54

55

56

57

58

59

60

61

62

63

64

65

66

67

68

69 *To the Editor:* An unexpected outbreak of chilblain has been reported in association with  
70 Coronavirus disease 19 (COVID-19)<sup>1</sup>. SARS-CoV-2 infection has been demonstrated in a few  
71 documented cases of chilblain. Chilblain may also be observed in acquired lupus and rarely as a  
72 manifestation of a familial disorder related to interferonopathies. To enhance understanding of this  
73 «epidemic chilblain» (EC) and their relevance to SARS-CoV-2 infection, we studied clinical, haemato-  
74 immunological, histopathological, immunohistochemical and virological characteristics of 7 EC cases  
75 and compared them with 11 previous cases of chilblain lupus erythematosus (CLE).  
76 EC patients were included between February and April 2020 and were suspected of COVID-19  
77 because they presented with COVID-19 symptoms or were in close contact with  
78 presumed/confirmed COVID-19 patients. Exclusion criteria were patients with previous chilblain  
79 episode, cold exposure preceding chilblain occurrence and history of known auto-immune disorder.  
80 For each patient, we collected demographic data, clinical and laboratory tests, including exhaustive  
81 haemato-immunological screening, cutaneous histology (including immunostaining for CD123, a  
82 plasmacytoid dendritic cells (pDCs) marker, and MxA, a type-I interferon (IFN-I)-induced protein) and  
83 virological studies.  
84 The clinico-biological findings of EC and CLE cases are summarized in Table 1. Hands, ears, or nose  
85 localisation were more frequently observed in CLE group (82% vs 0%). Anti-nuclear antibodies were  
86 only detected in the CLE group (91% vs 0%). Age of onset of chilblain, sex, pre-existing Raynaud's  
87 phenomenon and other immunological abnormalities did not differ between groups. Antineutrophils  
88 cytoplasmic antibodies (ANCA) and lupus-type circulating anticoagulant were found in two and one  
89 EC patients, without any clinical manifestation of ANCA vasculitis or thrombosis. No EC patient had  
90 cryoprotein, cold agglutinin or anticardiolipin antibodies.  
91 Our 7 EC cases were histologically similar to CLE. High expression of CD123 and MxA were observed  
92 in both groups (table 2).  
93 SARS-CoV-2 RNA detection performed at a median delay of 23 days after symptoms onset (10-36)  
94 was negative in nasopharyngeal, skin biopsies and plasma samples. Repeated SARS-CoV-2 IgG/IgA

95 tests were negative for all patients except for one case who showed an isolated IgA positivity (time  
96 between first symptoms and serologies ranged 21-51 days).

97 Active Human herpes virus type 6, 7, 8 and Epstein Barr virus infections were excluded by reliable  
98 tests (PCR).

99

100 These results confirmed that chilblains may be considered as a manifestation of high production of  
101 IFN-I as observed in interferonopathies. These patients may exhibit only IFN-I associated symptoms  
102 or minor forms of COVID-19 infection. High level of IFN-I was associated with moderate cases of  
103 COVID-19<sup>2</sup>. Interferon-induced proteins such as IFITM (interferon-induced trans-membrane) 1, 2 and  
104 3 inhibit early replication of several enveloped RNA viruses, such as MERS-coronaviruses<sup>3</sup>. In addition,  
105 active viral replication may not be necessary to mount an efficient IFN response in SARS-CoV  
106 infection<sup>4</sup>. IFN-I may also suppress antibody responses that might explains the negativity of the  
107 serologies in most patients with EC<sup>5</sup>.

108 SARS-Cov-2 infection may induce in some predisposed patients a high production of IFN-I responsible  
109 for a high innate immune protective response. This hypothesis provides additional arguments to  
110 propose early IFN treatment for infected high-risk patients.

111

112

113

114

115

116

117

118

119

120 References:

- 121 1. de Masson A, Bouaziz J-D, Sulimovic L, et al. Chilblains are a common cutaneous finding during  
122 the COVID-19 pandemic: a retrospective nationwide study from France. *J Am Acad Dermatol*.  
123 Published online May 4, 2020. doi:10.1016/j.jaad.2020.04.161
- 124 2. Impaired type I interferon activity and exacerbated inflammatory responses in severe Covid-19  
125 patients | medRxiv. Accessed May 14, 2020.  
126 <https://www.medrxiv.org/content/10.1101/2020.04.19.20068015v1>
- 127 3. Wrensch F, Winkler M, Pöhlmann S. IFITM Proteins Inhibit Entry Driven by the MERS-  
128 Coronavirus Spike Protein: Evidence for Cholesterol-Independent Mechanisms. *Viruses*.  
129 2014;6(9):3683-3698. doi:10.3390/v6093683
- 130 4. de Lang A, Baas T, Smits SL, Katze MG, Osterhaus AD, Haagmans BL. Unraveling the  
131 complexities of the interferon response during SARS-CoV infection. *Future Virol*. 2009;4(1):71-  
132 78. doi:10.2217/17460794.4.1.71
- 133 5. Fallet B, Narr K, Ertuna YI, et al. Interferon-driven deletion of antiviral B cells at the onset of  
134 chronic infection. *Sci Immunol*. 2016;1(4). doi:10.1126/sciimmunol.aah6817

135

136

137

138

139

140

141

142

143

144

145

146

147

148

## 149 TABLES

Table 1. Clinical and biological findings in EC and CLE

Variable	EC n = 7	CLE n = 11	P Value
Female, n (%)	4 (57)	7 (64)	1
Mean age (SD)	42 (10)	49 (15)	0.27
Previous Raynaud's phenomenon, No (%)	4 (57)	4 (36)	0.63
Previous other cutaneous symptoms, No (%)	3 <sup>a</sup> (43)	8 (73)	0.33
Feet-localized localisation, No (%)	7 (100)	2 (18)	<0.01
COVID-19 symptoms, No (%)	5 (71)	NA	-
Potential SARS-CoV-2 contact, No (%)	4 (57)	NA	-
Positive anti-nuclear antibodies, No (%)	0 (0)	10 (91)	<0.01
Presence of other immunological abnormalities, No (%)	3 <sup>b</sup> (43)	9 (82)	0.14

150 Abbreviations : SD= standard deviation ; NA= not applicable.

151 <sup>a</sup>Two patients had acrocyanosis and one patient had photosensitivity.152 <sup>b</sup>Two patients had ANCA and one patient had lupus-type circulating anticoagulant.

153

154

**Table 2. Histological and Immunohistochemical comparison between EC and CLE**

Variable	EC n = 7	CLE n = 11	P Value	
<b>Epidermis</b>				
Lymphocyte exocytosis, No (%)	3 (43)	7 (64)	0.63	
Confluent necrosis, No (%)	1 (14)	0 (0)	0.39	
Apoptotic keratinocytes, No (%)	2 (29)	4 (36)	1	
Vacuolized basement membrane zone, No (%)	1 (14)	8 (73)	<b>0.049</b>	
<b>Papillary dermis</b>				
Oedema, No (%)	4 (57)	2 (18)	0.14	
Lymphocyte infiltrate intensity score <sup>a</sup> , median (ranges)	2 (1 – 3)	2 (1 - 3)	0.34	
Lymphocyte infiltrate localization, No (%)				
	Perivascular localisation	7 (100)	11 (100)	1
	Interstitial localisation	3 (43)	8 (73)	0.33
Other inflammatory cell infiltrate, No (%)	2 (29)	3 (27)	1	
Lymphocytic vasculitis, No (%)	5 (71)	1 (9)	<b>0.01</b>	
Congestive vessels, No (%)	2 (29)	0 (0)	0.13	
Red blood cell extravasation, No (%)	4 (57)	1 (9)	<b>0.047</b>	
<b>Reticular and deep dermis</b>				
Lymphocyte infiltrate intensity score <sup>a</sup> , median (range)	2 (1 - 3)	2 (0 - 3)	0.77	
Lymphocyte infiltrate localization, No (%)				
	Perivascular	7 (100)	10 (91)	1
	Interstitial	0 (0)	0 (0)	1
	Peri-eccrine	6 (86)	7/10 (70) <sup>b</sup>	0.60
	Peri-neural	4 (57)	7/9 (78) <sup>c</sup>	0.59
Other inflammatory cell infiltrate, No (%)	2 (29)	3 (27)	1	
Lymphocytic vasculitis, No (%)	4 (57)	7 (64)	1	
Leucocytoclastic vasculitis, No (%)	1 (14)	1 (9)	1	
Congestive vessels, No (%)	3 (43)	1 (9)	0.24	



Median of neural section (range)	5 (2 – 9)	3 (0 – 4)	<b>0.008</b>
<b>Hypodermis<sup>d</sup></b>			
Perivascular lymphocyte infiltrate, No (%)	2/2 (100)	0/2 (0)	0.33
<b>Immunohistochemical features</b>			
Case with MxA+ cells, No (%)	7 (100)	10/10 (100) <sup>e</sup>	1
MxA expression, median value (range)	180 (105 – 280)	270 (120 – 300)	0.28
Case with CD123+ cells, No (%)	6 (86)	9/10 (90) <sup>e</sup>	1
CD123 expression, median value (range)	50 (0 – 60)	15 (0 – 100)	0.32
<b>Positive cutaneous DIF, No (%)</b>	0/3 (0) <sup>f</sup>	1/2 (50) <sup>g</sup>	0.4

155 Abbreviations: SD = standard deviation; MxA = myxovirus resistance protein A; DIF = Direct

156 Immunofluorescence

157 <sup>a</sup> Intensity was scored as follow: 0= absence, 1= rare, 2= moderated, 3= intense;

158 <sup>b</sup> One of CLE biopsy did not show eccrine gland;

159 <sup>c</sup> Two of CLE did not show nerve;

160 <sup>d</sup> Hypodermis was observed in 2 biopsies in each groups;

161 <sup>e</sup> One LCE could not have immunohistochemistry analyse;

162 <sup>f</sup> 3 DIF were performed in the epidemic chilblain group;

163 <sup>g</sup> 2 DIF were performed in the lupus chilblain group; SD = standard deviation.

164

165

166

167

168

169

170

171

172

173

174

175

176 An unexpected outbreak of chilblain has been observed with Coronavirus disease 19 (COVID-19)<sup>1,6</sup>.  
177 SARS-CoV-2 infection has been demonstrated in a few documented cases of chilblain<sup>7-9</sup>.  
178 Chilblain may also be observed in acquired lupus and rarely as a manifestation of a familial disorder  
179 related to interferonopathies<sup>10</sup>.  
180 To enhance understanding of these « epidemic chilblains » (EC) and their relevance to SARS-CoV-2  
181 infection, we studied clinical, haemato-immunological, histopathological, immunohistochemical and  
182 virological characteristics of seven EC cases and compared them with lupus chilblain erythematosus  
183 (CLE).  
184  
185 EC patients were included between February and April 2020 and were suspected of COVID-19  
186 because they presented with COVID-19 symptoms or were in close contact with  
187 presumed/confirmed COVID-19 patients. Exclusion criteria were patients with previous chilblain  
188 episode, cold exposure preceding chilblain occurrence and history of known auto-immune disorder.  
189 For each patient, we collected data about sex, age, clinical and laboratory tests, including haemato-  
190 immunological screening, cutaneous histology (immunostains for CD123 a plasmacytoid dendritic  
191 cells (pDCs) marker and MxA, a type-I interferon (IFN-I)-induced protein) and **virological studies**.  
192 The clinico-biological findings of EC and CLE cases are summarized in Table 1.  
193  
194  
195 Hands, ears, or nose localisation were more frequently observed in CLE group (82% vs 0%). ANA were  
196 detected only in the CLE group (91% vs 0%). Antineutrophils cytoplasmic antibodies (ANCA) and  
197 lupus-type circulating anticoagulant were found in two and one patient, without any manifestation  
198 of ANCA vasculitis or thrombosis. No patient had, cryoprotein, cold agglutinin or anticardiolipin  
199 antibodies.  
200 Age of onset of chilblain, sex, pre-existing Raynaud's phenomenon and other immunological  
201 abnormalities did not differ between groups.

202 Our 7 EC cases were histologically similar to CLE. High expression of CD123 and MxA were observed  
203 in both groups (table 2).

204

205 These results confirmed that chilblains may be considered as a manifestation of high production of  
206 IFN-I as observed in interferonopathies. These patients may exhibit only IFN-I associated symptoms  
207 or minor forms of COVID-19 infection. High level of IFN-I was associated with moderate cases of  
208 COVID-19<sup>2</sup>. Interferon-induced proteins such as IFITM (interferon-induced trans-membrane) 1, 2 and  
209 3 also inhibits early replication of several enveloped RNA viruses, such as MERS-coronaviruses<sup>11</sup>.  
210 In addition, active viral replication may not be necessary to mount an efficient IFN response in SARS-  
211 CoV infection<sup>4</sup>. IFN-I may also suppress antibody that explain the negativity of the serologies in most  
212 patients with EC.

213 SARS-Cov-2 infection may induce in some predisposed patients a high production of IFN-I responsible  
214 for a high innate immune protective response.

215 This hypothesis provides additional arguments to propose early IFN treatment for infected high-risk  
216 patients.

217

218

219

220

221

222

223

224

225

226

227

228 **REFERENCES :**

229

- 230 1. de Masson A, Bouaziz J-D, Sulimovic L, et al. Chilblains are a common cutaneous  
231 finding during the COVID-19 pandemic: a retrospective nationwide study from France.  
232 *J Am Acad Dermatol*. Published online May 4, 2020. doi:10.1016/j.jaad.2020.04.161
- 233 2. Impaired type I interferon activity and exacerbated inflammatory responses in severe  
234 Covid-19 patients | medRxiv. Accessed May 14, 2020.  
235 <https://www.medrxiv.org/content/10.1101/2020.04.19.20068015v1>
- 236 3. Wrensch F, Winkler M, Pöhlmann S. IFITM Proteins Inhibit Entry Driven by the  
237 MERS-Coronavirus Spike Protein: Evidence for Cholesterol-Independent Mechanisms.  
238 *Viruses*. 2014;6(9):3683-3698. doi:10.3390/v6093683
- 239 4. de Lang A, Baas T, Smits SL, Katze MG, Osterhaus AD, Haagmans BL. Unraveling the  
240 complexities of the interferon response during SARS-CoV infection. *Future Virol*.  
241 2009;4(1):71-78. doi:10.2217/17460794.4.1.71
- 242 5. Fallet B, Narr K, Ertuna YI, et al. Interferon-driven deletion of antiviral B cells at the  
243 onset of chronic infection. *Sci Immunol*. 2016;1(4). doi:10.1126/sciimmunol.aah6817
- 244 6. Galván Casas C, Català A, Carretero Hernández G, et al. Classification of the cutaneous  
245 manifestations of COVID-19: a rapid prospective nationwide consensus study in Spain  
246 with 375 cases. *Br J Dermatol*. Published online April 29, 2020. doi:10.1111/bjd.19163
- 247 7. Kolivras A, Dehavay F, Delplace D, et al. Coronavirus (COVID-19) infection-induced  
248 chilblains: A case report with histopathologic findings. *JAAD Case Rep*. Published  
249 online April 18, 2020. doi:10.1016/j.jdcr.2020.04.011
- 250 8. Locatelli AG, Robustelli Test E, Vezzoli P, et al. Histologic features of long lasting  
251 chilblain-like lesions in a pediatric COVID-19 patient. *J Eur Acad Dermatol Venereol*  
252 *JEADV*. Published online May 9, 2020. doi:10.1111/jdv.16617
- 253 9. Alramthan A, Aldaraji W. A case of COVID-19 presenting in clinical picture resembling  
254 chilblains disease. First report from the Middle East. *Clin Exp Dermatol*. Published  
255 online April 17, 2020. doi:10.1111/ced.14243
- 256 10. Zimmermann N, Wolf C, Schwenke R, et al. Assessment of Clinical Response to Janus  
257 Kinase Inhibition in Patients With Familial Chilblain Lupus and TREX1 Mutation.  
258 *JAMA Dermatol*. 2019;155(3):342-346. doi:10.1001/jamadermatol.2018.5077
- 259 11. Zhao X, Sehgal M, Hou Z, et al. Identification of Residues Controlling Restriction  
260 versus Enhancing Activities of IFITM Proteins on Entry of Human Coronaviruses.  
261 Williams BRG, ed. *J Virol*. 2017;92(6):e01535-17, /jvi/92/6/e01535-17.atom.  
262 doi:10.1128/JVI.01535-17